Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q3 EPS of ($0.30), $0.15 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $90.38 million versus the consensus estimate of $81.99 million.

GUIDANCE:

Mirum Pharmaceuticals, Inc. sees FY2024 revenue of $330-335 million, versus the consensus of $316.3 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.